



Proteomics International Signs Agreement with inVentiv Health Clinical Partnership offers developers full service biosimilar expertise on a global scale

February 2014 - PI has signed a co-marketing agreement with inVentiv Health Clinical, a leading provider of global clinical research and bioanalytical services. PI's agreement with inVentiv Health Clinical offers biosimilars developers the ability to seamlessly transition from characterisation to clinical trials thereby streamlining the process and providing a competitive advantage in the race to market.

[inVentiv Health Clinical Partnership](#)

Proteomics International Laboratories Relocation

March 2014 – PI's new purpose built, state-of-the-art laboratories are located at the Harry Perkins Institute of Medical Research in Perth, Western Australia. This new 8-storey building was opened by Prime Minister Tony Abbott in March 2014 and houses several highly regarded research organisations including the Lions Eye Institute, Heart Research Institute and the Lung Institute. PI's talented scientists have access to a full suite of analytical equipment, including the latest in mass spectrometry technology.

www.proteomics.com.au



Proteomics International biomarker study moves closer to a CDx test for diabetic kidney disease

April 2014 – PI has completed an important milestone towards the development of a companion diagnostic (CDx) test with the validation of seven protein biomarkers using the company's proprietary mass spectrometry approach. The mass spectrometry data was then cross-validated using immunoassays in collaboration with the KTH Royal Institute of Technology, Sweden, and Merck Millipore. These biomarkers are now available for out-licensing and PI is seeking a commercialisation partner to enter the RUO, LDT or IVD markets.

[Diabetic Kidney Disease Biomarker](#)

Expansion of Proteomics International Agency Network and Clients

PI's diagnostic and drug discovery research is underpinned by a commitment to excellence in fee-for-service analytical work alongside world first ISO 17025 accreditation. PI provides specialist analytical and consulting services to a global clientele. The company boasts an impressive array of blue chip pharmaceutical, biotechnology and academic clients worldwide, with a particular focus on the Asia-Pacific region.



Upcoming

The company is planning its next phase of growth, with the process well underway to list on the Australian stock market in the last quarter of 2014